Repository logo

Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes

Published version

Change log


Boughton, Charlotte  ORCID logo
Mubita, Womba 
Rubio, Jose 


Achieving healthy sleep supports general health and well-being1,2. Sleep disturbance in type 1 diabetes (T1DM) can be caused by factors including fear of hypoglycaemia and suboptimal glucose control3. For example, hypoglycaemia or hyperglycaemia can disturb sleep, through mechanisms including sympathetic activation and neuropathic pain, respectively4. Several observational studies have suggested that hybrid closed-loop (HCL) system initiation is associated with improved sleep,5,6 but these data could be limited by confounding and other biases. Moreover, different HCL devices could have differing effects on sleep; outcomes could be influenced by user age and the measures by which sleep is assessed. Our objectives, in older adults with T1DM, were to: a) assess the impact of an adaptive HCL system (CamAPS FX) on subjectively and objectively assessed sleep traits in a post hoc analysis of randomised controlled trial (RCT) data; and b) assess the relationship between glucose control and sleep traits in the trial cohort.



continuous glucose monitoring (CGM), insulin pump therapy, randomized trial, type 1 diabetes, Humans, Aged, Diabetes Mellitus, Type 1, Insulin, Blood Glucose, Insulin Infusion Systems, Hypoglycemic Agents, Insulin, Regular, Human, Sleep, Blood Glucose Self-Monitoring

Journal Title

Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics

Conference Name

Journal ISSN


Volume Title


Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK112176)
Medical Research Council (MR/T023899/1)
This work was funded by the National Institute of Diabetes and Digestive and Kidney Diseases under the grant number 1DP3DK112176-01 and the UK MRC Clinical Academic Research Partnership (MR/T023899/1). Additional support for the artificial pancreas work from National Institute for Health Research Cambridge Biomedical Research Centre, and JDRF. Dexcom supplied discounted continuous glucose monitoring devices